OverviewSuggest Edit
Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.2 billion in 2014 in more than 115 countries, with a direct commercial presence in 30 countries.
Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Ipsen’s commitment to oncology is exemplified through its growing portfolio in prostate cancer, bladder cancer or neuro-endocrine tumors. Ipsen also has a significant presence in primary care.
The Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative technological platforms, peptides and toxins, located in the heart of the leading biotechnological hubs (Les Ulis, Fr ; Slough/Oxford, UK ; Cambridge, US). In 2014, R&D expenditure totaled close to €187 million (about 15% of Group sales).
The Group has more than 4,500 employees.
| Type | Public | |
| Founded | 1929 | |
| HQ | Boulogne-Billancourt, FR | Map |
| Website | ipsen.com | |
| Employee Ratings | More | |
| Overall Culture | A+ | More |
Recent NewsAll News
- Ipsen Plunges as FDA Halts Bone Drug Trial in Children on Safety Concerns
- Verisk Elects Laura K. Ipsen to Board of Directors
- Ipsen and Blueprint Medicines announce exclusive global license agreement to develop and commercialize BLU-782 for the treatment of fibrodysplasia ossificans progressiva (FOP)
- Clayton, Dubilier & Rice erweitert europäisches Gesundheitswesen-Team mit der Ernennung von Jean-Luc Belingard, ehemaliger CEO von bioMérieux, Ipsen und Roche Diagnostics zum operativen Berater seiner Fonds
Latest Updates
| Employees (est.) (Dec 2021) | 5,700 | |
| Share Price (Nov 2021) | €86.4 | (+2%) |
Key People/Management at Ipsen
Aymeric le Chatelier
CFO
Marc de Garidel
Chairman
Richard Paulson
Chief Executive Officer - Ipsen North America
David Loew
Chief Executive Officer
Shahrzad Amirani
Vice President, Head of New Products & Innovation
Brad Carter
Sr. Director, Finance & Supply Chain
Ipsen Office Locations
Ipsen has offices in Boulogne-Billancourt, Glen Waverley, Merelbeke and Hoofddorp
Boulogne-Billancourt, FR (HQ)
65 Quai Georges Gorse
Glen Waverley, AU
540 Springvale Rd
Merelbeke, BE
Guldensporenpark 87
Hoofddorp, NL
Taurusavenue 33b
Ipsen Financials and Metrics
Ipsen Revenue
Market capitalization (10-Nov-2021) | 7.2b |
Closing stock price (10-Nov-2021) | 86.4 |
Ipsen's current market capitalization is €7.2 b.
Ipsen Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Clementia Pharmaceuticals | February 25, 2019 | $1.31 b |
Ipsen Environment, Social & Governance (ESG) Ratings
Ipsen Online and Social Media Presence
5.45k Twitter followers
Ipsen has 5.45k Twitter Followers. The number of followers has increased 0.8% month over month and increased 2.9% quarter over quarter
Ipsen's Trends
Twitter Engagement Stats for @IpsenGroup
2k
Tweets
1.3k
Following
5.4k
Followers
10
Tweets last 30 days
10
Avg. likes per Tweet
100%
Tweets with engagement
Ipsen Company Culture
Overall Culture
A+
82/100
CEO Rating
A+
79/100
Compensation
A+
85/100
Ipsen News and Updates
December 06, 2019
Ipsen Plunges as FDA Halts Bone Drug Trial in Children on Safety Concerns
Ipsen Plunges as FDA Halts Bone Drug Trial in Children on Safety Concerns
November 20, 2019
Verisk Elects Laura K. Ipsen to Board of Directors
JERSEY CITY, N.J., November 19, 2019 — Verisk (Nasdaq:VRSK), a leading data analytics provider, announces the addition of Laura K. Ipsen to its board of directors, effective January 1. read more
October 16, 2019
Ipsen and Blueprint Medicines announce exclusive global license agreement to develop and commercialize BLU-782 for the treatment of fibrodysplasia ossificans progressiva (FOP)
Expands Ipsen’s Rare Diseases portfolio to include BLU-782, a highly selective investigational ALK2 inhibitor for the treatment of FOP --read more
October 14, 2019
Clayton, Dubilier & Rice erweitert europäisches Gesundheitswesen-Team mit der Ernennung von Jean-Luc Belingard, ehemaliger CEO von bioMérieux, Ipsen und Roche Diagnostics zum operativen Berater seiner Fonds
NEW YORK und LONDON, 14. Oktober 2019 /PRNewswire/ -- Clayton, Dubilier & Rice („CD&R") gab heute die Ernennung von Jean-Luc Belingard, einer Führungskraft mit einer erfolgreichen Karriere bei weltweiten Pharmaunternehmen, zum Operating Advisor für CD&R Funds bekannt. Herr Belingard wird…
October 14, 2019
Clayton, Dubilier & Rice Expands European Healthcare Team with Appointment of Jean-Luc Belingard, former CEO of bioMérieux, Ipsen, and Roche Diagnostics, as an Operating Advisor to its Funds
NEW YORK and LONDON, Oct. 14, 2019 /PRNewswire/ -- Clayton, Dubilier & Rice ("CD&R") today announced the appointment of Jean-Luc Belingard, a senior executive with a successful career leading global pharmaceutical businesses, as an Operating Advisor to CD&R Funds. Mr. Belingard will work…
April 11, 2019
Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A.
MONTREAL, April 11, 2019 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA) ("Clementia" or the "Corporation") is pleased to announce that the Québec Superior Court issued earlier today a final order approving the previously announced statutory plan of arrangement under the Canada B…
Ipsen Blogs
February 13, 2020
FY2019 and beyond: paving the way for our next phase of growth.
Today, Ipsen announced its FY2019 results, and I would like to take a moment to reflect on another strong year and how we are paving the way for our next phase of growth. In 2019, we reported Group net sales which exceeded €2.5 billion for the first time, representing a 14.8% growth in sales. I […]…
February 10, 2020
Ipsen – Full Year 2019 Results Conference Call – February 13, 2020 at 2:30pm CET / 8:30 EST
Date: Thursday, February 13, 2020 Time: Conference call and webcast – 2:30pm CET / 8:30 EST Participants should dial in to the call approximately 5 to 10 minutes prior to its start. Standard International: +44 (0) 2071-928-000 France and continental Europe: + 33 (0) 1 76 70 0…
February 05, 2020
Ipsen in Neuroscience: A new decade of technological possibilities for Neuroscience at Ipsen
John Chaddock, VP Interim Global Head Neuroscience Therapeutic Area, Site Head Ipsen Bioinnovation, Ipsen As we welcome a new decade, it seems timely to reflect on the progress Ipsen has made in neuroscience and to reaffirm our commitment to continued innovation. For over 30 years, Ipsen has been a …
January 31, 2020
From collaboration to evaluation: developing a new way to evaluate patient wellbeing in NETs
Working with patients, for patients, underlines everything we do at Ipsen. Understanding their quality of life is a way we can measure the impact of our therapies. However, we need to be able to collect this information in an accurate and targeted way to ensure we can use it to improve our treatment…
December 20, 2019
Demerger of Mayroy SA and Internal reclassification of Ipsen shares
Luxembourg (France), 19 December 2019 – As previously announced in a press release dated November 5th, 2019Mayroy SA’s shareholders, (the Beaufour and Schwabe families), have now implemented the demerger of Mayroy SA (Ipsen’s controlling holding company) This demerger was completed on December 19th,…
December 09, 2019
On World Anti-Corruption Day, Ipsen re-affirms its commitment to the principles of the United Nations Global Compact Program
Understanding the importance of conducting business with the highest ethical standards, we asked Dominique Laymand, EVP, Ethics and Social Responsibility Chief Officer, three important questions to mark World Anti-Corruption Day: Dominique, why is anti-corruption so important in today’s world? F…
Ipsen Frequently Asked Questions
When was Ipsen founded?
Ipsen was founded in 1929.
Who are Ipsen key executives?
Ipsen's key executives are Aymeric le Chatelier, Marc de Garidel and Richard Paulson.
How many employees does Ipsen have?
Ipsen has 5,700 employees.
Who are Ipsen competitors?
Competitors of Ipsen include Zentiva, Idorsia and EMS Pharma.
Where is Ipsen headquarters?
Ipsen headquarters is located at 65 Quai Georges Gorse, Boulogne-Billancourt.
Where are Ipsen offices?
Ipsen has offices in Boulogne-Billancourt, Glen Waverley, Merelbeke and Hoofddorp.
How many offices does Ipsen have?
Ipsen has 4 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies